The University of Hong Kong: Carcinoma, Hepatocellular trials

The registry lists 14 Carcinoma, Hepatocellular studies with The University of Hong Kong as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer RecurrenceRecruitingNCT07839767
• Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot StudyRecruitingNCT07305428Not applicable
• Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2
• A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC on CTCompletedNCT06626087Not applicable
• Histotripsy (HistoSonics®) for Liver TumoursActive, not recruitingNCT06579833Not applicable
• TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingNCT04988945Phase 2
• SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular CarcinomaStatus unknownNCT04913480Phase 2
• Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPSCompletedNCT04868149Not applicable
• Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma PatientsStatus unknownNCT04601961Not applicable
• SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant WaitlistStatus unknownNCT03950102Not applicable
• SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCCCompletedNCT03578874Phase 2
• Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT02716766Phase 2
• Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular CarcinomaStatus unknownNCT00752063Phase 2
• Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCCCompletedNCT00234182Phase 1/2